article thumbnail

FDA approves breakthrough pneumonia therapy

Pharmaceutical Technology

Innoviva has snagged a win for its bacterial pneumonia drug Xacduro (durlobactam sodium + sulbactam) with a US Food and Drug Administration FDA approval for use in patients of ages 18 or older. per share in cash, following a 2020 deal that left the larger pharma company with 60% of the latter company’s outstanding shares.

article thumbnail

Top 10 Heart and Vascular Medications Based on Recent Sales Data

XTalks

The heart and vascular medication market continues to be a critical focus area for pharma companies, with billions of dollars in sales generated annually. Their widespread adoption is driven by strong clinical evidence, broad FDA-approved indications and continued advancements in treatment protocols.

Sales 104
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ViiV Healthcare long-acting HIV treatment secures FDA approval

Outsourcing Pharma

The HIV-focused pharma company announced the agency has approved Cabenuva for administration as few as six times a year for adults living with the virus.

article thumbnail

Italfarmaco’s Duvyzat Wins FDA Approval as First Nonsteroidal Treatment for All Genetic Variants of DMD

XTalks

Italy-based drugmaker Italfarmaco has won US Food and Drug Administration (FDA) approval for its oral medication Duvyzat (givinostat) for the treatment of Duchenne muscular dystrophy (DMD) in patients six years of age and older. Duvyzat received Priority Review, Orphan Drug and Rare Pediatric Disease designations from the FDA.

article thumbnail

Big pharma places big bets on antibody-drug conjugates

pharmaphorum

Big pharma companies like Pfizer are making significant investments in antibody-drug conjugates, a promising class of therapies. This article explores the growing interest and recent developments, including FDA approvals and the potential impact on the pharmaceutical industry.

Antibody 115
article thumbnail

Madrigal Pharma is first over the MASH finish line

pharmaphorum

Madrigal Pharma is first pharma company to get FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH)

article thumbnail

ESG Top Trends: Technology trends

Pharmaceutical Technology

Aprecia Pharmaceuticals’ Spritam, an anti-epileptic drug, is the first and only 3D-printed pharmaceutical, having received US Food and Drug Administration (FDA) approval in 2015. While large pharma companies have been slow in this area, Merck and GSK are now using 3D printing for clinical trials and manufacturing.